The transcription factor STAT5 mediates the increased breast cancer risk associated with a late age pregnancy, but intermittent anti-STAT5 treatment can lower this risk and thus prevent breast cancer.
GDC-0810 is a novel, orally bioavailable SERD that exhibits robust pre-clinical activity in models of ER+ breast cancer, including models of tamoxifen resistance, and those that express the ERα mutations, ER.Y537S and ER.D538G.
The study of a recurrent breast cancer MAGI3 truncation reveals the role of MAGI3 in regulating the Hippo effector YAP and highlights premature mRNA cleavage and polyadenylation as a mechanism underlying cancer development.
Copy number alteration heterogeneity exists in many shapes and forms in breast cancer genomes and single-cell genomics is a powerful tool to further our understanding of its nature and significance.
Breast cancer resistant to either doxorubicin or epirubicin relies on distinct primary metabolic processes, which can be targeted to reduce cancer progression.
Splicing by QKI and RBFOX1 regulates the function of the actin-binding protein FLNB by creating an isoform frequently observed in human cancers that dictates tumor cell plasticity.
3D culture of breast cancer in biologically relevant ECM potentiates the growth-inhibitory effects of unacylated ghrelin and AZP-531, and clinical response may be predictable based on a MAPK gene signature.
A novel first-in-class small molecule (ERX-11) that interacts with and disrupts the interactome of the estrogen receptor (ER), blocks the growth of ER-positive breast cancers, including those that are resistant to currently approved hormonal agents.
